CARGO Therapeutics, Inc. Common Stock Total Liabilities
CARGO Therapeutics, Inc. Common Stock total liabilities. Based on the latest financial reports, CARGO Therapeutics, Inc. Common Stock (CRGX) has total liabilities worth $20.91 Million USD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check CARGO Therapeutics, Inc. Common Stock (CRGX) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of CARGO Therapeutics, Inc. Common Stock (2021–2024)
Total liabilities of CARGO Therapeutics, Inc. Common Stock from 2021 to 2024. This chart illustrates how CARGO Therapeutics, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. Explore CARGO Therapeutics, Inc. Common Stock (CRGX) investment intensity to see how much of total assets are deployed in long-term investments.
CARGO Therapeutics, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of CARGO Therapeutics, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Utah Medical Products Inc
NASDAQ:UTMD
|
USA | $4.01 Million |
|
XRF Scientific Ltd
AU:XRF
|
Australia | AU$8.67 Million |
|
Pasifik Gayrimenkul Yatirim Ortakligi AS
IS:PSGYO
|
Turkey | TL46.97 Billion |
|
BRC Inc.
NYSE:BRCC
|
USA | $132.63 Million |
|
Asia Sermkij Leasing Public Company Limited
BK:ASK
|
Thailand | ฿49.42 Billion |
|
Tudor Gold Corp
V:TUD
|
Canada | CA$17.37 Million |
|
AS Tallinna Vesi
F:A1T
|
Germany | €255.92 Million |
|
Mark Dynamics Indonesia Tbk PT
JK:MARK
|
Indonesia | Rp105.73 Billion |
Liability Composition Analysis (2021–2024)
This chart breaks down CARGO Therapeutics, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see CRGX asset base.
Liquidity & Leverage Metrics
CARGO Therapeutics, Inc. Common Stock Total Liabilities Ratios Explained
CARGO Therapeutics, Inc. Common Stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 12.37 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CARGO Therapeutics, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CARGO Therapeutics, Inc. Common Stock (2021–2024)
The table below shows the annual total liabilities of CARGO Therapeutics, Inc. Common Stock from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $53.83 Million | +12.96% |
| 2023-12-31 | $47.65 Million | +4.77% |
| 2022-12-31 | $45.48 Million | +871.98% |
| 2021-12-31 | $4.68 Million | -- |
About CARGO Therapeutics, Inc. Common Stock
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, focused on designing, engineering, and developing potentially curative cell therapies for cancer patients in the United States. The company develops CRG-023, a tri-specific CAR T product candidate which is in phase 1 that targets tumor cells with three B-cell malignancies; and allogeneic platform, a universal vector solution design… Read more